Several antibodies that inhibit the PD-1 pathway by blocking either PD-1 or PD-L1 are being developed for clinical use in a variety of tumour types and clinical settings (Table 1). These agents ...

近日，上海交通大学附属胸科医院陆舜教授团队在SCIENCE CHINA Life Sciences (《中国科学：生命科学》英文版) 发表题为“Effectiveness of PD-1/PD-L1 inhibitors in ...

San Francisco, US Tuesday, February 18, 2025, 09:00 Hrs [IST] ...

7 The programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) pathways regulate the immune system by enhancing the regulatory T cells (Tregs) function and inhibiting T ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related ...